In brief, doxycycline was provided to HFD and LFD fed mice beginning at 6 weeks of age to drive oncogene dependent primary breast tumorigenesis, following which tumor regression was induced by doxycycline withdrawal clomiphene moa 48 times the risk with chemotherapy plus tamoxifen